Medical Marketing International has decided to concentrate on its cancer treatments.
It will focus on oncology treatments based on its DNA vaccine and ruthenium chemotherapy technologies. It will also look to acquire other cancer treatments.
MMI has generated positive results from trials for a DNA vaccine for prostate cancer based on its Genvax technology. It plans to initiate phase Ib/IIa trials for a commercial product for the treatment of prostate cancer and lymphoma/myeloma.
It will also focus its attention on ONCO4417, the most promising of its ruthenium compounds. A clinical trial based on this compound should start next year.
Any other treatments being developed will either be sold or licensed to other companies. That includes its anti-viral ribozyme technology aimed at infectious diseases.
The shares were unchanged at 19.75p.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.